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Background: Reconstruction of biliary drainage after liver transplantation (LTx) in patients with primary
sclerosing cholangitis (PSC) has been a matter of controversy. Over recent years, the traditional method
of Roux-en-Y hepaticojejunostomy (RY) has been challenged by duct-to-duct (DD) biliary reconstruction.
Methods: This study represents a retrospective review of biliary complications, patient and graft survival
after LTx in PSC patients based on type of biliary reconstruction. Outcomes of DD reconstruction in this
group of patients and non-PSC patients are compared.
Results: A total of 53 primary LTx procedures were performed for PSC between August 2005 and July
2010. Seven patients were excluded because unexpected cholangiocarcinoma was found in the explants
(n = 3) or because they received partial livers (n = 4). Biliary reconstruction was performed as DD in 18
patients and RY in 28 patients. There were no bile leaks. Anastomotic stricture occurred in two (11%)
patients in the DD group and one (4%) in the RY group. Two (7%) patients in the RY group developed
non-PSC intrahepatic strictures and one had recurrence of PSC. Rates of 1- and 3-year patient and graft
survival in the RY and DD groups were 96.7% and 96.7%, and 100% and 94.5%, respectively. In a group
of 34 randomly selected patients transplanted for a non-PSC diagnosis with DD reconstruction during the
same period, the anastomotic stricture rate was 9% and 1- and 3-year patient and graft survival rates
were 97.0% and 88.5%; differences were not significant.
Conclusions: Duct-to-duct biliary reconstruction at the time of LTx in selected PSC patients is both
effective and safe, and shows outcomes comparable with those of RY reconstruction in these patients
and those of DD reconstruction in non-PSC patients.
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Introduction
Primary sclerosing cholangitis (PSC) is a chronic and progressive
cholestatic liver disease of unknown aetiology, which is character-
ized by diffuse obliterative inflammation and fibrosis of the intra-
and extrahepatic bile ducts leading to recurrent episodes of
cholangitis, biliary cirrhosis, increased risk of cholangiocarci-
noma (CCA), and, ultimately, death from liver failure or cancer in
a high percentage of patients.1,2 Therapeutic options, including
medical therapy,3 endoscopic intervention4–6 and surgical exci-
sion,7 have shown limited results. Liver transplantation (LTx) is
the only definitive treatment to offer longterm survival in PSC
patients with cirrhosis and liver failure.8,9
The preferred method of biliary reconstruction in conven-
tional LTx for most indications is duct-to-duct choledocho–
choledochostomy (DD). Roux-en-Y choledochojejunostomy
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(RY) has been the procedure of choice whenDD is not possible for
a variety of reasons in LTx. In many transplant programmes, RY is
the established procedure of biliary reconstruction in patients
with PSC. This is mostly because of concern that undetected
residual PSC disease may remain in the extrahepatic bile duct, that
the disease may recur and that strictures may form or CCA
develop in the remnant recipient distal bile duct. In recent years,
the traditional method of RY after LTx in PSC patients has been
challenged by some transplant centres and reports of safe DD
biliary reconstruction with outcomes similar to those of RY in
selected groups of patients with PSC have been published.10–12
The purpose of this study was to evaluate our experiences of
DD and RY biliary reconstruction after LTx in PSC patients. A
single-centre, retrospective analysis was performed to evaluate
patient and graft survival and the incidence of biliary complica-
tions in these two groups of patients. Outcomes of DD biliary
reconstruction in PSC patients were compared with outcomes of
DD in a cohort of patients transplanted for other indications
during the same period.
Materials and methods
From August 2005 to July 2010, 693 LTx procedures were per-
formed. A retrospective review of outcomes of 53 primary LTx
procedures for PSC with respect to the type of biliary reconstruc-
tion was conducted with the approval of our institutional review
board. Seven patients were excluded because unexpected CCAwas
found in the explant (n = 3) or because they received partial livers
only (n = 4). Biliary reconstruction was undertaken as DD in 18
and RY in 28 of the remaining 46 patients. The median follow-up
period was 36 months. In addition to the biochemical tests, post-
operative complication rates and rates of 1- and 3-year patient
and graft survival were compared between the two groups. The
outcomes of 34 patients who underwent DD reconstruction after
LTx for non-PSC indications were also compared with those of
our cohort of 18 patients who underwent DD reconstruction after
LTx for PSC.
The decision to utilize DD biliary reconstruction was based on
the presence of: (i) normal pre-transplant cholangiographic fea-
tures of the extrahepatic bile ducts; (ii) normal findings in brush-
ing or cytology; (iii) intraoperative evaluation of the common bile
duct by the operating surgeon; (iv) absence of periductal oedema,
inflammation and wall thickening; (v) normal-looking mucosa;
(vi) easy passage of biliary probes through the bile duct and into
the duodenum, and (vii) a distal bile duct diameter of 5 mm.
The diagnosis of biliary strictures was suggested by elevations
in liver biochemistry, in particular, in total bilirubin and/or alka-
line phosphatase (ALP) levels. This was confirmed by subsequent
imaging with magnetic resonance cholangiopancreatography, ret-
rograde endoscopic cholangiopancreatography (ERCP) or percu-
taneous transhepatic cholangiography.
Results
There were no significant differences between the two groups in
serum levels of bilirubin or ALP at 1 and 3 months after LTX
(Table 1). No anastomotic bile leaks developed in the post-LTx
period in either the DD or RY patient groups. Anastomotic stric-
tures occurred in two patients in the DD group and one patient in
the RY group (Table 2). Strictures in the DD group were treated
successfully utilizing ERCP and dilatation with stenting. The only
anastomotic stricture in the RY group was treated by a percuta-
neous approach. None of these patients required operative recon-
struction of the strictures. Two patients in the RY group developed
localized intrahepatic biliary strictures and one patient was diag-
nosed with recurrent PSC 4 years after LTx. One patient in the DD
group died of unknown reasons 2 years after LTx and one patient
in the RY group died shortly after LTx secondary to sepsis and
complications of enterocutaneous fistula, not related to the RY.
Rates of 1- and 3-year patient and graft survival did not differ
significantly between the two groups (Table 2). No cancer devel-
oped in the bile duct remnant in any patient.
The comparison of outcomes in 34 randomly selected patients
who underwent LTx with DD biliary reconstruction for non-PSC
Table 1 Bilirubin and alkaline phosphatase (ALP) levels at 1 and 3 months postoperatively
Bilirubin at 1 month, mg/dl Bilirubin at 3 months, mg/dl ALP at 1 month, IU/l ALP at 3 months, IU/l
PSC with DD reconstruction 1.34  0.86 0.72  0.51 231.76  185.56 164.25  143.80
PSC with RY reconstruction 1.22  1.45 0.53  0.21 167.15  99.90 178.00  137.64
Values are mean  standard deviation.
All P-values were >0.05, indicating statistical insignificance.
PSC, primary sclerosing cholangitis; DD, duct-to-duct; RY, Roux-en-Y.
Table 2 Comparison of the outcomes of duct-to-duct (DD) and Roux-en-Y (RY) biliary reconstruction
DD reconstruction RY reconstruction P=value
Patients, n 18 28
Anastomotic stricture, n (%) 2 (11%) 1 (4%) 0.312
1-year patient and graft survival 100% 96.7% 0.412
3-year patient and graft survival 94.5% 96.7% 0.742
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indications with outcomes in the 18 PSC patients who underwent
DD reconstruction showed similar results in the two groups with
respect to the rate of post-LTx anastomotic strictures, as well as
patient and graft survival (Table 3).
Discussion
Biliary complications after LTx, especially at the anastomosis, are
relatively common and can be categorized as resulting from tech-
nical, vascular, graft-related or immunological factors.13–16 These
complications are thought to be more prevalent and disease recur-
rence is considered to be a cause of graft loss after LTx in patients
transplanted for PSC.16–18
Traditionally, RY hepaticojejunostomy has been the method of
choice for reconstruction of the biliary tree after LTx in PSC
patients. This preference has mainly represented a response to the
assumption that the distal bile duct remnant may potentially be
involved with the active disease process and that stricture forma-
tion may result from disease progression or recurrence, or that the
bile duct remnant may represent a site at increased risk for devel-
opment of CCA.
In the light of better understanding of the pathology of biliary
involvement in PSC, and evidence that the extrahepatic biliary
system is not always affected by the disease process, some authors
have questioned whether RY should be so strictly regarded as the
only choice for biliary reconstruction. Recently, several reports
from different transplant centres have presented data supporting
the feasibility of conventional DD biliary reconstruction in
selected groups of patients transplanted for PSC and have dem-
onstrated excellent outcomes comparable with those of tradi-
tional RY biliary reconstruction.10–12 Therefore, we examined
whether the type of biliary reconstruction has any impact on
incidences of complications and outcomes at our centre.
In our patient population, the incidence of biliary anastomotic
stricture in the DD group was 11%, which was not significantly
higher than the 4% incidence in the RY group. By contrast, intra-
hepatic biliary stricture occurred in 7% of the RY group, but none
was detected in the DD group. There were no bile leaks in either
group. In a study by Vito et al., biliary anastomotic stricture
occurred in 19% of DD and 10% of RY patients transplanted for
PSC, and biliary leak occurred in 6% of DD and 20% of RY
patients.11 These authors also compared outcomes in their
PSC-DD patients with those in a group of patients undergoing
LTx with DD biliary construction for primary biliary cirrhosis
(PBC). Anastomotic stricture occurred in 10% of the PBC-DD
patients and 19% of the PSC-DD group, but this difference was
not statistically significant.11 In the present study, outcomes in 18
DD patients were compared with those in a group of 34 patients
who received LTX for a non-PSC diagnosis and biliary stricture
rates were identified as 11% and 10%, respectively. In another
study by Heffron and colleagues, outcomes in 38 patients who
underwent RY were compared with those in 22 patients who
underwent DD biliary reconstruction after LTX for PSC.10 The
authors found no significant difference in rates of anastomotic
stricture formation, bile leak, need for revision or recurrence of
PSC between the two groups of patients.10
Welsch and Wigmore reviewed outcomes of 362 PSC patients
reported in the UK Liver Transplant Registry, of whom 264 under-
went RY and 98 underwent DD biliary reconstruction.12 They
found no significant difference between the two groups in rates of
bile leak. However, biliary strictures were seen more frequently in
the DD group (8% vs. 2%; P = 0.05).12 A similar pattern was
observed in our patient population, but the lower number of cases
in each of our study armsmake the study insufficiently powered to
show equivalence. Welsch and Wigmore also noted a significantly
higher rate of loss of patients with functioning grafts in the DD
group, but did not disclose the causes of patient loss in this popu-
lation.12 They also did not clarify whether patients who received
DD biliary reconstruction did so because their intraoperative
general condition indicated it was appropriate, or whether the
decision to perform DD reconstruction was based on a specific
protocol pertaining to the condition of the recipient’s bile duct,
which was followed at all the reporting centres.12
Biliary reconstruction with RY has been suggested to represent
a risk factor for the development of non-anastomotic biliary stric-
ture (NAS) after LTx.19,20 In the present study, we observed two
patients with NAS in the RY group and none in the DD group.
Hoekstra et al. reviewed a series of 486 consecutive adult PSC LTx
patients, in whom biliary reconstruction was performed as either
DD or RY depending on the condition of the extrahepatic bile
duct.21 These authors observed a 17% incidence of NAS in their
patients. By univariate analysis, PSC as the indication for LTx, type
of biliary reconstruction (RY vs. DD), and postoperative cytome-
galovirus infection were found to be significantly associated with
NAS. By multivariate logistic regression analysis, only PSC as the
indication for LTx and cytomegalovirus infection remained as
independent risk factors for NAS. Roux-en-Y reconstruction was
not found to be an independent risk factor for NAS.21






Number of patients, n 18 34
Anastomotic stricture, n (%) 2 (11%) 3 (9%) 0.788
1-year patient and graft survival 100% 97.0% 0.466
3-year patient and graft survival 94.5% 88.5% 0.472
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Cholangiocarcinoma develops in 8–18% of patients with long-
standing PSC.22,23 This is based on development of bile duct epi-
thelial dysplasia, which is reported to precede the development of
CCA.24,25 Whether this reflects the result of immunological factors
directed towards the biliary epithelium, alterations in the compo-
sition of bile in patients with PSC, or a continuous inflammatory
response by cytokines produced in these patients is not clear.26–28
One of the arguments against DD biliary reconstruction in
patients transplanted for PSC is the risk for development of CCA
in the bile duct remnant. It has been suggested that as much
remnant recipient bile duct as possible should be excised in PSC
patients with extrahepatic disease or in the presence of epithelial
dysplasia at the time of LTx.9 However, in patients with a healthy
extrahepatic biliary system, there is no clear evidence to prohibit
the use of the remnant bile duct for DD reconstruction. There are
no reports in the literature of the appearance of CCA in the
remnant bile duct after RY reconstruction or when the remnant
bile duct is used in DD reconstruction in PSC patients.
In recent years, there have been reports of the use of choledo-
choduodenostomy for biliary reconstruction after LTx in PSC
patients without significant differences in patient and graft sur-
vival. However, higher rates of complications such as anastomotic
stricture and leak, or cholangitis, have been reported after this
procedure.29,30
We appreciate that this study is not powered to show the
equivalence of the two procedures; however, we believe that DD
biliary reconstruction after LTx for PSC is a viable alternative to
the traditional RY reconstruction in a selected group of patients. It
is an especially useful alternative in the presence of normal-
looking bile duct when the condition of the small intestine is less
favourable for a RY procedure. It appears to be safe and is techni-
cally less demanding, and results in comparable longterm compli-
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